Drug-Shortage List Under Scrutiny After FDA Reversal
By Dan McKay · October 22, 2024, 4:43 PM EDT
A federal agency's unusual flip-flop this month on whether to allow copycat versions of a lucrative weight-loss and diabetes drug may cause regulators to move more cautiously as they weigh how...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login